Juglanin

SKU: orb1217964

Description

Juglanin is a JNK activator. Juglanin with inflammation and anti-tumor activities. It can induce apoptosis and autophagy on human breast cancer cells.

Key Properties

• CAS Number: 5041-67-8
• MW: 418.35
• Purity: >98% (HPLC)
• Formula: C₂₀H₁₆O₁₀
• SMILES: O=C1C(O[C@H]2[C@@H]([C@H]([C@H](CO)O2)O)O)=C(C3=CC=C(O)C=C3)OC4=CC(O)=CC(O)=C14
• Target: Apoptosis
• Solubility: Methanol:16 mg/mL (38.25 mM; Need ultrasonic)

Bioactivity

• In Vivo:
  Animal model: Tumor-transplanted mouse model. Dosage: 10-20 mg/kg. Administration: Intraperitoneal injection (i.p.), daily, 7 days. Result: Increased levels of cleaved Caspase-9 and Caspase-3, LC3BI, LC3BII and phosphorylated JNK. Increased dead cells and apoptosis proportion in juglanin-treated tumor tissues. Increase in mean areas that stained positively cleaved Caspase-3 in juglanin-treated tumor tissues. Animal model: C57BL6 male mice. Dosage: 10-30 mg/kg. Administration: Intraperitoneal injection (i.p.), 5 times weekly. Result: Increased number of platform crossings and expanded time in target quadrant. Decreased the expression level of α-synuclein, pro-inflammatory cytokines (IL-1β, TNF-α, IL-18 and COX-2), TLR-4, MyD88, CD14, Aβ, phosphorylation of Tau, Ibal and neurotrophic factor (BDNF). Reversed LPS-triggered effect on synaptic markers, up-regulating the expression of SYP, PSD-95 and SNAP-25.Restored TH levels in the hippocampus of mice in a dose-dependent manner. Decreased p-IKKα, p-IκBα and p-NF-κB levels combinated with LPS. Decreased the GFAP-positive cells. Animal model: C57BL/6 male mice. Dosage: 80 mg/kg. Administration: i. g. , daily, 1-21 days. Result: Improved the survial rate of the BLM (HY-108345)-treated mice. Decreased the expression of BALF, CXCL1, IL-6, TNF-α, MPO activity, TGF-β1, and its down-streaming proteins (fibronectin/MMP-9/α-SMA/collagen I). Reduced the number of total cells, neutrophils and macrophages in BALF.
  Read more...
• In Vitro:
  Cell Viability Assay Cell line: MCR-5 cell. Concentration: 0-40 μM. Incubation time: 0-72 h. Result: Reduced the cell viability of MCR-5 after 24 h exposure at 160 μM. Reduced the cell viability of MCR-5 after 72 h exposure at 40 μM. Western blot analysis. Cell line: MCF-7, SKBR3. Concentration: 0-10 μM. Incubation time: 24 h. Result: Increased the expressions of phosphorylated Chk2, Chk2, phosphorylated Cdc25C, phosphorylated Cdc2, p27, cyclin D, Bad, Bax and decreased the levels of Cdc25C, Cdc2, Bcl-2.Activated caspases and led to Casapse-9, Casapse-8 and Caspase-3 cleavage. Increased the level of JNK phosphorylation. Western blot analysis. Cell line: Lipopolysaccharides (LPS, HY-D1056)-treated AST cells. Concentration: 40-160 μM. Incubation time: 24 h. Result: Decreased the expression of TLR4, MyD88, CD14, p-IKKα, p-IκBα, p-NF-κB, GFAP, BDNF, Aβ and p-Tau induced by LPS (HY-D1056). Increased the level of SYP, PSD-25 and SNAP-25.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

Apoptosis